

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrEUCRISA™

Crisaborole Ointment

Ointment: 2% w/w (2 mg/g) for Topical Use

Phosphodiesterase-4 (PDE-4) Inhibitor

Pfizer Canada ULC
17 300 Trans-Canada Highway
Kirkland, Quebec
H9J 2M5

Date of Initial Authorization:
JUN 07, 2018

Date of Revision:
AUG 29, 2023

™ Anacor Pharmaceuticals, LLC, owner / Pfizer Canada ULC

Submission Control Number: 267872

RECENT MAJOR LABEL CHANGES

4 Dosage and Administration, 4.2 Recommended Dose and Dosage Adjustment	08/2023
---	---------

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics.....	4
1.2 Geriatrics.....	4
2 CONTRAINDICATIONS	4
4 DOSAGE AND ADMINISTRATION	4
4.2 Recommended Dose and Dosage Adjustment	4
4.4 Administration	4
4.5 Missed Dose	5
5 OVERDOSAGE	5
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	5
7 WARNINGS AND PRECAUTIONS	5
7.1 Special Populations	5
7.1.1 Pregnant Women	5
7.1.2 Breast-feeding.....	6
7.1.3 Pediatrics.....	6
7.1.4 Geriatrics.....	6
8 ADVERSE REACTIONS	6
8.1 Adverse Reaction Overview	6
8.2 Clinical Trial Adverse Reactions	6
8.2.1 Clinical Trial Adverse Reactions – Pediatrics.....	7
8.3 Less Common Clinical Trial Adverse Reactions.....	7
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other	

	Quantitative Data.....	8
	8.5 Post-Market Adverse Reactions.....	8
9	DRUG INTERACTIONS	8
	9.2 Drug Interactions Overview	8
	9.3 Drug-Behavioural Interactions.....	8
	9.4 Drug-Drug Interactions	9
	9.5 Drug-Food Interactions.....	9
	9.6 Drug-Herb Interactions	9
	9.7 Drug-Laboratory Test Interactions.....	9
10	CLINICAL PHARMACOLOGY.....	9
	10.1 Mechanism of Action	9
	10.2 Pharmacodynamics.....	9
	10.3 Pharmacokinetics.....	9
11	STORAGE, STABILITY AND DISPOSAL.....	11
12	SPECIAL HANDLING INSTRUCTIONS.....	11
	PART II: SCIENTIFIC INFORMATION	12
13	PHARMACEUTICAL INFORMATION	12
14	CLINICAL TRIALS	12
	14.1 Clinical Trials by Indication	12
	Atopic Dermatitis	12
	14.2 Comparative Bioavailability Studies	16
15	MICROBIOLOGY	17
16	NON-CLINICAL TOXICOLOGY	17
	PATIENT MEDICATION INFORMATION	18

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

EUCRISA (crisaborole ointment, 2 %) is indicated for:

- topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 3 months of age and older. (see 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment)

1.1 Pediatrics

Pediatrics (3 months to <18 years): Based on the data submitted and reviewed by Health Canada, the safety and effectiveness of EUCRISA have been established in pediatric patients age 3 months and older for topical treatment of mild to moderate atopic dermatitis.

Pediatrics (<3 months of age): No data are available to Health Canada, therefore, Health Canada has not authorized an indication for pediatric patients below the age of 3 months.

1.2 Geriatrics

Geriatrics (≥ 65 years of age): Evidence from clinical studies of EUCRISA did not include sufficient numbers of patients 65 years of age and over to determine whether they respond differently from younger patients.

2 CONTRAINDICATIONS

EUCRISA is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.

For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.

4 DOSAGE AND ADMINISTRATION

4.2 Recommended Dose and Dosage Adjustment

EUCRISA should be applied topically twice daily to all affected areas of skin for management of active disease.

For maintenance, once affected areas are clear or almost clear, a layer of ointment is to be applied once daily to the most commonly affected areas. If signs and symptoms of the disease worsen, a layer of ointment is to be applied twice daily to affected areas. Patients responding to up to 8 weeks of twice daily active disease treatment (i.e., lesions cleared or almost cleared) are suitable for once daily maintenance treatment.

4.4 Administration

EUCRISA should be applied topically to all affected areas of skin.

EUCRISA is for topical use only and not for oral, ophthalmic or intravaginal use.

4.5 Missed Dose

Advise patients if they forget to use EUCRISA as directed, to apply it as soon as possible, then go back to their regular schedule.

5 OVERDOSAGE

EUCRISA is not for oral use.

There are no data from clinical trials regarding signs and symptoms of overdose of EUCRISA. Overdosage with EUCRISA is not anticipated with dermal application. If surplus EUCRISA has been applied, the excess should be thoroughly wiped off.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Topical	Ointment 20 mg of crisaborole per gram (2%) of white to off-white ointment	butylated hydroxytoluene, edetate calcium disodium, mono- and di-glycerides, paraffin, white petrolatum, propylene glycol.

EUCRISA contains 2% crisaborole (w/w) in a petrolatum-based, white to off-white ointment and is for topical use. Each gram of EUCRISA contains 20 mg of crisaborole in an ointment containing white petrolatum, propylene glycol, mono- and di-glycerides, paraffin, butylated hydroxytoluene, and edetate calcium disodium.

EUCRISA is supplied in 30g, 60g, and 100g multilaminar tubes.

7 WARNINGS AND PRECAUTIONS

Hypersensitivity

Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA. Hypersensitivity should be suspected in the event of severe pruritus, swelling and erythema at the application site or at a distant site. If signs and symptoms of hypersensitivity occur, discontinue EUCRISA immediately and initiate appropriate therapy.

7.1 Special Populations

7.1.1 Pregnant Women

There is no available data with EUCRISA in pregnant women to inform the drug-associated risk for major birth defects and miscarriage. In animal reproduction studies, there were no adverse developmental effects observed with oral administration of crisaborole in pregnant rats and rabbits

during organogenesis at doses up to 3 and 2 times, respectively, the maximum recommended human dose (MRHD).

7.1.2 Breast-feeding

It is unknown if EUCRISA is excreted in human milk. There is no information available on the effects of the drug on the breastfed infant or the effects on milk production after topical application of EUCRISA to women who are breastfeeding. EUCRISA is systemically absorbed. The lack of clinical data during lactation precludes a clear determination of the risk of EUCRISA to a breastfed infant. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EUCRISA and any potential adverse effects on the breastfed infant from EUCRISA or from the underlying maternal condition. Because many drugs are excreted in human milk, precaution should be exercised.

7.1.3 Pediatrics

Pediatrics (3 months to <18 years): Based on the data submitted and reviewed by Health Canada, the safety and effectiveness of EUCRISA for topical treatment of mild to moderate atopic dermatitis have been established in pediatric patients age 3 months and older. Use of EUCRISA in this age group is supported by data from two 28 day adequate, vehicle-controlled safety and efficacy trials which included 1,313 pediatric patients ages 2 to <18 years old of whom 874 received EUCRISA. The most commonly reported adverse reaction in subjects 2 years and older was application site pain. Additionally, use of EUCRISA in pediatric patients aged 3 months to less than 2 years was supported by data from a 28-day open-label, safety and pharmacokinetics (PK) trial in 137 subjects. No new safety signals were identified in subjects 3 months to less than 2 years of age (see ADVERSE REACTIONS, ACTION AND CLINICAL PHARMACOLOGY and CLINICAL TRIALS).

The safety and effectiveness of EUCRISA in pediatric patients below the age of 3 months have not been established.

7.1.4 Geriatrics

Evidence from clinical studies of EUCRISA did not include sufficient numbers of patients 65 years of age and over to determine whether they respond differently from younger patients.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

The most common adverse drug reactions reported in clinical trials among patients with mild to moderate atopic dermatitis 2 years of age and older have been application site reactions.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

In two randomized, double-blind, parallel-group, vehicle-controlled Phase 3 clinical trials (Studies AN2728-AD-301 and AN2728-AD-302), 1012 patients 2 to 79 years of age with mild to moderate atopic dermatitis were treated with EUCRISA twice daily for 4 weeks. The adverse reaction reported by $\geq 1\%$ of EUCRISA-treated patients is listed in Table 2.

Table 2: Adverse Reaction Occurring in $\geq 1\%$ of Patients in Atopic Dermatitis Trials through Week 4

Adverse Reaction	EUCRISA Twice Daily N=1012 n (%)	Vehicle Twice Daily N=499 n (%)
Application site pain ^a	45 (4.45%)	6 (1.20%)

^a Refers to skin sensations such as burning or stinging.

In one double-blind, vehicle-controlled, maintenance trial (C3291035), 497 subjects 5 months to 79 years of age with mild to moderate atopic dermatitis entered into an open-label period and were first treated with EUCRISA twice daily for up to 8 weeks. The adverse reactions observed in the open-label period were consistent with the known safety profile of twice daily EUCRISA. During the double-blind maintenance period, 135 subjects out of 270 randomized subjects were treated with EUCRISA and 135 subjects received vehicle once daily for 52 weeks or until they developed a flare. The adverse reactions observed with once daily EUCRISA treatment were similar to vehicle.

8.2.1 Clinical Trial Adverse Reactions – Pediatrics

In a multicenter, open-label, uncontrolled trial, 137 pediatric subjects aged 3 months to less than 2 years were treated with EUCRISA twice daily for 4 weeks. Overall, the safety profile of EUCRISA in this age group was consistent with that of Studies AN2728-AD-301 and AN2728-AD-302 in subjects 2 years of age and older.

Use of EUCRISA twice daily in pediatric patients aged 3 months to 17 years is further supported by data from the open-label period of up to 8 weeks in C3291035, a vehicle-controlled maintenance trial in 327 pediatric subjects. Once daily use of EUCRISA in 82 pediatric subjects 3 months to 17 years is supported by data from the 52-week double-blind maintenance period of C3291035. No new safety concerns were identified in C3291035 in pediatric subjects.

8.3 Less Common Clinical Trial Adverse Reactions

The following adverse reactions were observed in $< 1\%$ of patients treated with EUCRISA.

General disorders and administration site conditions: application site reactions (including contact dermatitis and pruritus)

Skin and subcutaneous tissue disorders: flare of atopic dermatitis.

In an open-label, single arm, long-term safety study, 517 patients 2 to 72 years of age (including 454 patients 2 to 17 years of age), who had completed one of the Phase 3 studies without safety issues that precluded further treatment, were treated with EUCRISA twice daily intermittently for up to 48 weeks in 28 day on-treatment or off-treatment cycles. A total of 9 (2%) patients discontinued the therapy due to adverse events. The most frequently reported adverse events included atopic dermatitis, application site pain, and application site infection.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Results for clinical laboratory testing have not identified clinically important changes from baseline to the end of study in mean or median values for any hematology or biochemistry parameters in any of the clinical studies in patients with atopic dermatitis.

8.5 Post-Market Adverse Reactions

The following adverse reactions have been identified during post-approval use of EUCRISA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

Application site reactions

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

In vitro studies using human liver microsomes indicated that under the conditions of clinical use, crisaborole and metabolite 1 are not expected to inhibit cytochrome P450 (CYP) 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4.

In vitro studies using human liver microsome for metabolite 2 showed that it did not inhibit activities of CYP2C19, 2D6, and 3A4; was a weak inhibitor of CYP1A2 and 2B6; and a moderate inhibitor of CYP2C8 and 2C9.

In vitro studies in human hepatocytes showed that under the conditions of clinical use, crisaborole and metabolites 1 and 2 are not expected to induce CYP enzymes.

In vitro studies showed that crisaborole and metabolite 1 did not inhibit the activities of uridine diphosphate (UDP)-glucuronosyltransferase (UGT) 1A1, 1A4, 1A6, 1A9, 2B7, and 2B15. Metabolite 2 did not inhibit UGT1A4, 1A6, 2B7, and 2B15. Metabolite 2 showed weak inhibition of UGT1A1, however, no clinically significant drug interactions are expected between crisaborole (and its metabolites) and UGT1A1 substrates at therapeutic concentrations. Metabolite 2 showed moderate inhibition of UGT1A9 and may result in a moderate increase of the concentrations of sensitive UGT1A9 substrates.

In vitro studies indicate that under the condition of clinical use, crisaborole and metabolites 1 and 2 are not expected to cause clinically significant interactions with substrates of P-glycoprotein and organic anionic or cationic transporters. Crisaborole and metabolite 1 are not expected to inhibit breast cancer resistance protein (BCRP); metabolite 2 is expected to inhibit BCRP at therapeutic concentrations.

9.3 Drug-Behavioural Interactions

Drug-behavioural interactions have not been established.

9.4 Drug-Drug Interactions

The most sensitive enzyme, CYP2C9, was further investigated in a clinical trial with coadministration of EUCRISA with warfarin, a CYP2C9 substrate. The results of this study showed no drug interaction potential.

9.5 Drug-Food Interactions

Interactions with food have not been established, as not applicable for topical products.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. While the specific mechanism(s) by which crisaborole exerts its therapeutic action is not well defined, crisaborole reduces the production of some inflammatory cytokines implicated in the pathophysiology of atopic dermatitis.

10.2 Pharmacodynamics

At therapeutic doses, EUCRISA ointment is not expected to prolong QTc to any clinically relevant extent. In a thorough QT/QTc study of healthy volunteers, there was no clinically important prolongation of QT/QTc interval induced by either crisaborole or its metabolites and there were no clinically significant effects on heart rate or PR or QRS intervals.

A randomized clinical study was carried out to determine the potential of EUCRISA ointment, 2%, to induce sensitization and to cause irritation by repeated topical application to normal skin of healthy volunteers (18 years of age or older) under controlled conditions. In this study, EUCRISA showed no evidence of skin sensitization potential. Some skin irritations (e.g. erythema, edema and papules) were reported.

10.3 Pharmacokinetics

Table 3 - Summary of EUCRISA Pharmacokinetic Parameters in 2 – 17 year old patients with mild to moderate atopic dermatitis and treated BSA range from 27% - 92%

	C_{max} ng/ml	T_{max} (hrs, median (range))	AUC₀₋₁₂(ng.hr/mL)
Steady State Mean (SD)	127 (196)	3.00 (3.00 – 24.0)	949 (1240)

Absorption

The pharmacokinetics (pK) of EUCRISA were investigated in 33 pediatric patients 2 to 17 years of age

with mild to moderate atopic dermatitis and a mean \pm SD body surface area (BSA) involvement of $49 \pm 20\%$ (range 27% to 92%). In this study, patients applied approximately 3 mg/cm² of EUCRISA ointment (dose range was approximately 6 g to 30 g per application) twice daily for 8 days. The lower limit of quantification for the pK assay used to detect presence of crisaborole in plasma was 0.2 ng/mL.

Plasma concentrations were quantifiable in all the patients. The mean \pm SD maximum plasma concentration (C_{max}) and area under the concentration time curve from 0 to 12 hours post dose (AUC_{0-12}) for crisaborole on Day 8 were 127 ± 196 ng/mL and 949 ± 1240 ng·h/mL, respectively (Table 3). Systemic concentrations of crisaborole were at steady state by Day 8. Based on the ratios of AUC_{0-12} between Day 8 and Day 1, the mean accumulation factor for crisaborole was 1.9.

The PK of EUCRISA were investigated in 18 subjects 3 months to less than 24 months of age. Excluding outlier values from 5 subjects the mean \pm SD C_{max} and AUC_{0-12} for crisaborole were 188 ± 100 ng/mL and 1164 ± 550 ng·h/mL, respectively.

Distribution:

Based on an in vitro study, crisaborole is 97% bound to human plasma proteins.

Metabolism:

Crisaborole is substantially metabolized into inactive metabolites. The major metabolite 5-(4-cyanophenoxy)-2-hydroxyl benzylalcohol (metabolite 1), is formed via hydrolysis; this metabolite is further metabolized into downstream metabolites, among which 5-(4-cyanophenoxy)-2-hydroxyl benzoic acid (metabolite 2), formed via oxidation, is also a major metabolite.

Pharmacokinetics of metabolites 1 and 2 were assessed in the PK study described above and the systemic concentrations were at or near steady state by Day 8. Based on the ratios of AUC_{0-12} between Day 8 and Day 1, the mean accumulation factors for metabolites 1 and 2 were 1.7 and 6.3, respectively.

Elimination

Renal excretion of metabolites is the major route of elimination.

Special Populations and Conditions

- **Pediatrics**

A multicenter, open-label maximal use, systemic exposure study with a pK Phase and a non-pK Safety Phase was conducted in children and adolescents with mild to moderate AD. Based on the pK exposures, no difference was seen in pK exposures in patients between the various age cohorts (2 to <18 years old).

A separate PK study evaluated 18 subjects aged 3 months to <2 years of age. Following EUCRISA twice daily administration, large variations in plasma concentrations of crisaborole were observed, with 5 infants exhibiting more than 2-fold higher AUC compared to adults. Sampling methodology errors may have contributed to this result. When excluding values associated with potential sampling errors, results indicated comparable systemic crisaborole exposures in infants and toddlers as observed in older patients at similar treated BSA. However, an actual increase in exposure in infants and toddlers relative to older patients cannot be excluded.

- **Geriatrics**

PK profiles of crisaborole and its two metabolites have not been assessed in geriatric subjects.

- **Hepatic Insufficiency**

PK profiles of crisaborole and its two metabolites have not been assessed in patients with hepatic impairment.

- **Renal Insufficiency**

PK profiles of crisaborole and its two metabolites have not been assessed in patients with renal impairment.

11 STORAGE, STABILITY AND DISPOSAL

Store below 25°C.

12 SPECIAL HANDLING INSTRUCTIONS

Advise the patient or caregivers to read the Patient Medication Information.

Hypersensitivity:

Advise patients to discontinue EUCRISA and seek medical attention immediately if signs or symptoms of hypersensitivity occur (see WARNING and PRECAUTIONS).

Administration Instructions:

Advise patients or caregivers that EUCRISA is for external use only and is not for ophthalmic, oral, or intravaginal use.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Crisaborole


Chemical name: 4(1-hydroxy-1,3,-dihydrobenzo[c][1,2]oxaborol-5-yloxy)benzonitrile

4-[(1,3-dihydro-1-hydroxy-2,1- benzoxaborol-5-yl)oxy]benzonitrile

5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy- [2,1]-benzoxaborole

Molecular formula and molecular mass: C₁₄ H₁₀ BNO₃, 251.1 daltons

Structural formula:



Physicochemical properties: EUCRISA contains 2% crisaborole (w/w) in a petrolatum-based, white to off-white ointment and is for topical use. The active ingredient, crisaborole, is a phosphodiesterase-4 (PDE-4) inhibitor. Crisaborole drug substance is freely soluble in common organic solvents such as isopropyl alcohol and propylene glycol, and insoluble in water.

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

Atopic Dermatitis

Trial Design and Study Demographics

Table 4 - Summary of Trial Design and Patient Demographics for Pivotal Phase 3 Clinical Trials in Atopic Dermatitis

Study #	Trial design	Dosage, route of administration and duration	Study patients (n)	Mean age (Range) (years) And Gender	Efficacy Endpoints
AN2728-AD-301	Multi-center, randomized, double-blind, vehicle-	Crisaborole ointment 2%, topical application twice daily for 28 days	503	12.0 (2-65) Male: 43.5% Female: 56.5%	The primary efficacy endpoint was the proportion of patients at Day 29 who achieved success, defined as

Study #	Trial design	Dosage, route of administration and duration	Study patients (n)	Mean age (Range) (years) And Gender	Efficacy Endpoints
	controlled	Vehicle ointment topical application twice daily for 28 days	256	12.4 (2-63) Male: 44.1% Female: 55.9%	an ISGA of clear (0) or almost clear (1) with a 2-grade or greater improvement from baseline.
AN2728-AD-302	Multi-center, randomized, double-blind, vehicle-controlled	Crisaborole ointment 2%, topical application twice daily for 28 days	513	12.6 (2-79) Male: 45.0% Female: 55.0%	The secondary efficacy endpoints were the proportion of patients at Day 29 with ISGA of clear (0) or almost clear (1) and the time to success in ISGA.
		Vehicle ointment topical application twice daily for 28 days	250	11.8 (2-79) Male: 44.8% Female: 55.2%	
C3291002	Multi-center, open-label, single arm	Crisaborole ointment 2%, topical application twice daily for 28 days	137	1.1 (0.25-1.9) Male: 64.2% Female: 35.8%	Exploratory analysis using key endpoints as in studies AN2728-AD-301 and AN2728-AD-302, noted above.
C3291035	Multi-center, randomized, double-blind, vehicle-controlled	Crisaborole ointment 2%, topical application once daily for 52 weeks	135	22.6 (1.15 – 79.1) Male: 47.4% Female: 52.6%	Time of flare-free maintenance up until the onset of the first flare during the 52-week maintenance period.
		Vehicle ointment topical application once daily for 52 weeks	135	21.8 (0.45 – 76.1) Male: 43.7% Female: 56.3%	

The efficacy and safety of EUCRISA (crisaborole ointment, 2 %) was evaluated in two pivotal Phase 3, multicenter, randomized, double-blind, parallel-group, vehicle-controlled trials (Studies AN2728-AD-301 and AN2728-AD-302) that were identical in study design (Table 4). Patients with mild to moderate atopic dermatitis were randomized 2:1 to receive EUCRISA or vehicle applied twice daily for 28 days. Based on the amount of drug used in 28 days, the mean drug (EUCRISA Ointment, 2%) used per patient per application was approximately 3 grams in these clinical trials.

A total of 1,522 patients 2 to 79 years of age were enrolled in these studies. Overall, demographic characteristics and baseline disease characteristics were balanced between two treatment groups. The mean age was 12.3 years in the EUCRISA group and 12.1 years in the vehicle group. About 62% of patients in both treatment groups were 2 to 11 years of age, and 31-37% of patients were 2 to 6 years of age. At baseline, 38.5% of the patients had an Investigator’s Static Global Assessment (ISGA) of mild

(2), and 61.5% had an ISGA of moderate (3), in the overall assessment of atopic dermatitis (erythema, induration/papulation, and oozing/crusting) on a severity scale of 0 to 4. The mean treatable percent body surface area at baseline was 18% (range from 5% to 95%). Moderate or severe baseline pruritus was reported in approximately 70% of patients.

In a multicenter, open-label, uncontrolled trial (Study C3291002), 137 pediatric subjects aged 3 months to less than 2 years were treated with EUCRISA twice daily for 4 weeks. The primary endpoint of safety was evaluated through 4 weeks, with support from pharmacokinetic analyses showing similar drug exposure to older subjects.

One Phase 3, randomized, double-blind, vehicle-controlled trial (C3291035) assessed the efficacy and safety of EUCRISA once daily over 52 weeks as maintenance treatment to reduce the incidence of flares in adult and pediatric patients (3 months to 17 years) with mild to moderate atopic dermatitis, who responded to EUCRISA twice daily during open-label treatment of up to 8 weeks.

A total of 497 subjects 5 months to 79 years of age with a 2% to 90% treatable BSA, entered into an open-label period to receive EUCRISA twice daily for up to 8 weeks. At baseline, 66.2% of the subjects had an ISGA of moderate (3), and 33.6% had an ISGA of mild (2), in the overall assessment of atopic dermatitis (erythema, induration/papulation, and oozing/crusting) on a severity scale of 0 to 4.

Of the 497, a total of 270 subjects aged 5 months to 79 years, who achieved both ISGA success (score of clear [0] or almost clear [1] with a ≥ 2 grade improvement from baseline) and EASI50 response (at least 50% improvement from baseline in EASI scores) were randomized 1:1 into a double-blind maintenance period to receive EUCRISA once daily or vehicle for 52 weeks. At baseline in the maintenance period, 60.0% of the subject had an ISGA of almost clear (1) and 38.5% has an ISGA of clear (0).

Study Results

AN2728-AD-301 and AN2728-AD-302

In Phase 3 trials: AN2728-AD-301 and AN2728-AD-302, the primary efficacy endpoint was the proportion of patients at Day 29 who achieved success, defined as an ISGA of clear (0) or almost clear (1) with a 2-grade or greater improvement from baseline, comparing EUCRISA-treated patients to vehicle-treated patients. The secondary efficacy endpoints included the proportion of patients at Day 29 with ISGA of clear (0) or almost clear (1), and the time to success in ISGA.

The results of the primary efficacy endpoint from two pivotal trials are summarized in Table 5.

Table 5: Results of the Primary and Secondary Efficacy Endpoints in Patients with Mild to Moderate Atopic Dermatitis at Day 29

	AN2728-AD-301		AN2728-AD-302	
	EUCRISA Twice Daily (N=503)	Vehicle Twice Daily (N=256)	EUCRISA Twice Daily (N=513)	Vehicle Twice Daily (N=250)
Primary Efficacy Endpoint --- Success in ISGA ^a	32.8%	25.4%	31.4%	18.0%
p-value	0.038		<0.001	
Secondary Efficacy Endpoint --- ISGA Clear (0) or Almost Clear (1) ^b	51.7%	40.6%	48.5%	29.7%
p-value	0.005		<0.001	

^a Defined as an ISGA of clear (0) or almost clear (1) with a 2-grade or greater improvement from baseline.

^b A 2-grade or greater improvement from baseline was not required.

The results of the primary efficacy endpoint showed that patients treated with EUCRISA (crisaborole ointment, 2 %) had a statistically significant higher rate (32.8% and 31.4%) of success in ISGA at Day 29 when compared with those treated with Vehicle (25.4% and 18.0%) in both pivotal trials, respectively.

Similarly, the results of the secondary efficacy endpoint showed that patients treated with EUCRISA (crisaborole ointment, 2 %) had a statistically significant higher rate (51.7% and 48.5%) of clear or almost clear ISGA scores ratings at Day 29 when compared with those treated with Vehicle (40.6% and 29.7%) in both pivotal trials, respectively. The time to success in ISGA was also statistically significantly earlier in the EUCRISA group than in the vehicle group in both trials.

C3291002:

The efficacy of EUCRISA in children 3 months to <2 years of age is extrapolated from efficacy in patients aged 2 year and older. The key exploratory efficacy endpoint in Study C3291002 was the proportion of patients who achieved treatment success, defined as an ISGA grade of clear or almost clear with a 2-grade or greater improvement from baseline. The results on ISGA were comparable to those observed among EUCRISA-treated subjects in Studies AN2728-AD-301 and AN2728-AD-302.

C3291035:

Efficacy was demonstrated by a statistically significant prolonged duration of flare-free days when comparing EUCRISA-treated subjects with vehicle-treated subjects (Table 6).

Table 6: Efficacy Results of the First Flare in Subjects with Mild to Moderate Atopic Dermatitis During the Flare-Free Maintenance Period (through Week 52)


	C3291035	
	EUCRISA Once Daily (N=125)	Vehicle Once Daily (N=129)
Flare-free days until onset of first flare (Median days [95% CI])*	111 (56, 224)	30 (28, 56)
Subjects with First Flare, n (%)	81 (64.8)	96 (74.4)
Subjects Censored, n (%)	44 (35.2)	33 (25.6)
Hazard Ratio (95% CI) ^a	0.646 (0.477, 0.875)	
p-value ^b	0.0034	

* Estimated by the Kaplan-Meier (product limit) method; CI: Confidence Interval; LS: Least Squares

^a Hazard ratio based on stratified Cox regression model.

^b p-value based on stratified log-rank test.

Figure 1: Kaplan-Meier Curve of Flare-Free Maintenance in Study C3291035



14.2 Comparative Bioavailability Studies

Not applicable.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

Carcinogenicity:

In an oral carcinogenicity study in Sprague-Dawley rats, oral doses of 30, 100, and 300 mg/kg/day crisaborole were administered to rats once daily for 104 weeks. A drug-related higher incidence of benign granular cell tumors in the uterus with cervix and vagina (combined) was noted in 300 mg/kg/day crisaborole treated female rats (1.5 times the MRHD on an AUC comparison basis). The clinical relevance of this finding is unknown.

In a dermal carcinogenicity study in CD-1 mice, topical doses of 2%, 5% and 7% crisaborole ointment were administered once daily for at least 99 (females) or 104 (males) weeks. No drug-related neoplastic findings were noted at topical doses up to 7% crisaborole ointment (1 times the MRHD on an AUC comparison basis).

Genotoxicity:

Crisaborole revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (Ames assay and human lymphocyte chromosomal aberration assay) and one in vivo genotoxicity test (rat micronucleus assay).

Reproductive and Developmental Toxicology:

Rat and rabbit embryo-fetal development was assessed after oral administration of crisaborole. Crisaborole did not cause adverse effects to the fetus at oral doses up to 300 mg/kg/day in pregnant rats during the period of organogenesis (3 times the MRHD on an area under the curve (AUC) comparison basis). No crisaborole-related fetal malformations were noted after oral treatment with crisaborole in pregnant rats at doses up to 600 mg/kg/day (13 times the MRHD on an AUC comparison basis) during the period of organogenesis. Maternal toxicity was produced at this high dose of 600 mg/kg/day in pregnant rats and was associated with decreased fetal body weight and delayed skeletal ossification. Crisaborole did not cause adverse effects to the fetus at oral doses up to the highest dose tested of 100 mg/kg/day in pregnant rabbits during the period of organogenesis (2 times the MRHD on an AUC comparison basis).

In a prenatal/postnatal development study, pregnant rats were treated with crisaborole at doses of 150, 300, or 600 mg/kg/day by oral gavage during gestation and lactation (from gestation day 7 through day 20 of lactation). Crisaborole did not have any adverse effects on fetal development at doses up to 300 mg/kg/day (3 times the MRHD on an AUC comparison basis). Maternal toxicity was produced at the high dose of 600 mg/kg/day in pregnant rats and was associated with findings of stillbirths, pup mortality, and reduced pup weights.

No effects on fertility were observed in male or female rats that were administered oral doses up to 600 mg/kg/day crisaborole (13 times the MRHD on an AUC comparison basis) prior to and during early pregnancy.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PrEUCRISA™

Crisaborole Ointment

Read this carefully before you start taking **EUCRISA** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **EUCRISA**.

What is EUCRISA used for?

- EUCRISA is used for adults and children (3 months of age and older) to treat mild to moderate eczema (atopic dermatitis).

How does EUCRISA work?

EUCRISA belongs to a group of medicines known as a “phosphodiesterase-4 (PDE-4) inhibitor”. It is a non-steroid prescription medicine and the exact way it works is not known. EUCRISA is thought that it reduces the amount of substances in the body that trigger the rash and itchiness caused by eczema.

What are the ingredients in EUCRISA?

Medicinal ingredient: Crisaborole.

Non-medicinal ingredients: Butylated hydroxytoluene, edetate calcium disodium, mono- and di-glycerides, paraffin, propylene glycol, and white petrolatum.

EUCRISA comes in the following dosage forms:

Ointment: 2% w/w (20 mg per gram) of crisaborole.

Do not use EUCRISA if:

- you or your child are allergic to crisaborole or any of the other ingredients in EUCRISA.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take EUCRISA. Talk about any health conditions or problems you may have, including if you:

- are pregnant or planning to become pregnant. It is not known if EUCRISA may harm your unborn baby.
- are breast-feeding or planning to breast-feed. It is not known if EUCRISA passes into breast milk. Talk with your healthcare professional about the best way to feed your baby if you take EUCRISA.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with EUCRISA:

- There are no relevant interactions with EUCRISA at this time.

How to take EUCRISA:

- Use EUCRISA exactly as directed by your healthcare professional.
- EUCRISA is a topical medicine that is only to be applied onto the affected area(s) of the skin. Do NOT use in your eyes, mouth, or vagina.
- Rinse with water if this medicine gets in you or your child's eyes, mouth, or vagina.
- Wash your hands after applying EUCRISA, unless you are using it to treat eczema on your hands. All caregivers who apply EUCRISA for someone else should wash their hands after applying it.

Usual dose:

Your healthcare professional will tell you how often to apply EUCRISA. This will be based on your or your child's medical condition and response to the EUCRISA.

The usual dose is to apply a thin layer of EUCRISA to affected area(s) twice daily.

When your or your child's eczema is clear or almost clear, your healthcare professional may reduce your dose to once daily to the most commonly affected area(s). However, if your or your child's eczema worsens, your healthcare professional may increase your dose to twice daily to the affected area(s).

Overdose:

If you think that you or your child has applied too much EUCRISA, thoroughly wipe it off.

If you think you, or a person you are caring for, have taken too much EUCRISA, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you or your child miss or forget to use EUCRISA, apply it as soon as you remember. Then go back to the regular dosing schedule. Do NOT apply twice as much the next time you use it.

What are possible side effects from using EUCRISA?

These are not all the possible side effects you may have when taking EUCRISA. If you experience any side effects not listed here, tell your healthcare professional.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
VERY COMMON			
Application site reactions: burning, itching, inflamed skin, or stinging.	X		
RARE			
Allergic reactions (at or near the application site): hives, itching, swelling, or redness.			X

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store EUCRISA below 25°C.

Keep out of reach and sight of children.

If you want more information about EUCRISA:

- Talk to your healthcare professional.
- Find the full Product Monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website

(<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website (<http://www.Pfizer.ca>), or by calling 1-800-463-6001.

This leaflet was prepared by Pfizer Canada ULC.

Last Revised: AUG 29, 2023